Ensacove (ensartinib) — Medica
Non-Small Cell Lung Cancer
Initial criteria
- Patient is age ≥ 18 years
- Patient has locally advanced or metastatic disease
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- The mutation was detected by an approved test
- Patient has not previously received an ALK inhibitor
Approval duration
1 year